Overview and Scope
Hypertrophic cardiomyopathy (HCM) therapeutics refers to a treatment of a condition in which the heart muscle becomes abnormally thick or hypertrophied. The thickening heart muscle makes the heart ineffective at pumping blood. Hypertrophic cardiomyopathy (HCM) therapeutics aim to reduce symptoms and guard against sudden cardiac death in high-risk patients.
Sizing and Forecast
The hypertrophic cardiomyopathy (hcm) therapeutics market size has grown steadily in recent years. It will grow from $1.3 billion in 2023 to $1.34 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to diagnostic advancements, increased disease awareness, drug development and approvals, rising healthcare expenditure, government initiatives and funding.
The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.48 billion in 2028 at a compound annual growth rate (CAGR) of 2.6%. The growth in the forecast period can be attributed to genetic research and personalized medicine, emerging therapeutic modalities, collaborative research initiatives, patient-centric healthcare models, lobal health initiatives. Major trends in the forecast period include advancements in targeted therapies, personalized medicine and genetic testing:, drug pipeline expansion, collaborations and partnerships, patient-centric approaches.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/hypertrophic-cardiomyopathy-hcm-therapeutics-global-market-report
Segmentation & Regional Insights
The hypertrophic cardiomyopathy (hcm) therapeutics market covered in this report is segmented –
1) By Drug Type: Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Other Drug Types
2) By Device Type: Defibrillators, Pacemakers, Other Device Types
3) By End User: Hospitals, Clinics
North America was the largest region in the hypertrophic cardiomyopathy (HCM) therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the hypertrophic cardiomyopathy (HCM) therapeutics market report during the forecast period. The regions covered in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9914&type=smp
Major Driver Impacting Market Growth
The increasing incidence of cardiovascular diseases (CVD) is expected to propel the growth of the hypertrophic cardiomyopathy (HCM) therapeutics market. Cardiovascular disease (CVD) is a condition that affects the heart or blood vessels. Cardiovascular diseases include heart irregularities such as atrial fibrillation, ventricular fibrillation, and atrioventricular block that require long-term monitoring. The primary need for therapeutics treatment for hypertrophic cardiomyopathy aims to alleviate symptoms and avoid sudden cardiac death in high-risk patients. For instance, according to the October 2022 report of the Center For Disease Control and Prevention (CDCP), a US-based national public health agency, in the United States, one person dies from cardiovascular disease every 36 seconds, and CVD is responsible for nearly 836,546 deaths in the United States alone in 2021. Therefore, the increasing incidence of cardiovascular diseases (CVD) drives the hypertrophic cardiomyopathy (HCM) therapeutics market.
Key Industry Players
Major companies operating in the hypertrophic cardiomyopathy (HCM) therapeutics market are developing breakthrough therapies such as next-generation cardiac myosin inhibitors to offer substantial improvement over existing therapies. A next-generation cardiac myosin inhibitor is a novel class of therapeutic agents designed to selectively target and inhibit cardiac myosin, a protein involved in muscle contraction. For instance, in December 2021, Cytokinetics Incorporated, a US-based biopharmaceutical company received breakthrough therapy designation from the FDA for aficamten, its next-generation cardiac myosin inhibitor developed for treating symptomatic obstructive hypertrophic cardiomyopathy. Aficamten demonstrated significant reductions in left ventricular outflow tract pressure gradients and improved symptoms in patients. The Breakthrough Therapy Designation acknowledges its potential to provide substantial improvement over existing therapies.
The hypertrophic cardiomyopathy (hcm) therapeutics market report table of contents includes:
1. Executive Summary
2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Characteristics
3. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Trends And Strategies
4. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market – Macro Economic Scenario
5. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size and Growth
…
31. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Benchmarking
32. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
34. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
